Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

1991 ◽  
Vol 27 (5) ◽  
pp. 561-565 ◽  
Author(s):  
Marco Bregni ◽  
Salvatore Siena ◽  
Massimo Di Nicola ◽  
Gianni Bonadonna ◽  
Alessandro M. Gianni
Keyword(s):  
Cancer Chemotherapy ◽  
Alkylating Agent ◽  
Nausea And Vomiting ◽  
High Dose

Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy

1984 ◽  
Vol 22 (3) ◽  
pp. 9-11
Keyword(s):  
Cancer Chemotherapy ◽  
Cytotoxic Drugs ◽  
Nausea And Vomiting ◽  
High Dose

Nausea and vomiting caused by cytotoxic drugs often resist anti-emetics in conventional doses.1,2 Nabilone and high-dose metoclopramide are two new preparations specifically for the treatment of vomiting induced by cancer chemotherapy. We have recently discussed domperidone which is also used for this purpose.3

Corticosteroids and lorazepam as antiemetics in cancer chemotherapy

1986 ◽  
Vol 24 (12) ◽  
pp. 46-48
Keyword(s):  
Cancer Chemotherapy ◽  
Cardiac Arrhythmias ◽  
Cytotoxic Drug ◽  
Nausea And Vomiting ◽  
High Dose

In patients receiving cancer chemotherapy nausea and vomiting are the unwanted effects that often prove most troublesome.1 The incidence and severity of such symptoms depend on the type and dose of cytotoxic drug(s) used and on patient susceptibility, some drugs, particularly cisplatin, doxorubicin, dacarbazine and mustine, are particularly emetic but the incidence is compounded by anticipatory vomiting which develops in about a quarter of patients if symptoms have been poorly controlled during earlier courses.2 Treatment is hampered because it is difficult to predict who will develop symptoms and which therapy might be effective.3 We recently reviewed the antiemetics nabilone, high-dose metoclopramide4 and domperidone.5 Unfortunately, these are not always effective and may be associated with unacceptable unwanted effects (for instance intravenous domperidone can cause cardiac arrhythmias). Studies now suggest that corticosteroids and lorazepam may be useful additions.

Doxorubicin, Cisplatin, High-dose Methotrexate, and Ifosfamide for Osteosarcoma

2007 ◽  
Vol 42 (9) ◽  
pp. 801-811 ◽  
Author(s):  
John E. Mbue ◽  
Dominic A. Solimando ◽  
J. Aubrey Waddell
Keyword(s):  
Cancer Chemotherapy ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Malignant Diseases ◽  
Dose Methotrexate ◽  
Toxic Agents

The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.

High-Dose Alkylating Agent Therapy: A Review of Clinical Experiences

1984 ◽  
Vol 1 (3) ◽  
pp. 227-238 ◽  
Author(s):  
M.A. CORNBLEET ◽  
R.C.F. LEONARD ◽  
J.F. SMYTH
Keyword(s):  
Alkylating Agent ◽  
High Dose ◽  
Clinical Experiences

Unresectable Non-Small Cell Lung Cancer Chemotherapy with High-Dose Cisplatin and Etoposide

Oncology ◽  
1985 ◽  
Vol 42 (4) ◽  
pp. 224-228 ◽  
Author(s):  
Giorgio V. Scagliotti ◽  
Donatella Lodico ◽  
Felice Gozzelino ◽  
Franco Bardessono ◽  
Carlo Albera ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Chemotherapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Dose ◽  
Small Cell Lung

High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.

1985 ◽  
Vol 3 (2) ◽  
pp. 245-251 ◽  
Author(s):  
S B Strum ◽  
J E McDermed ◽  
D F Liponi
Keyword(s):  
Patient Preference ◽  
Nausea And Vomiting ◽  
High Dose ◽  
Chemotherapy Response ◽  
Antiemetic Efficacy ◽  
Study Results ◽  
Nausea And Emesis ◽  
To Receive ◽  
Single Blind ◽  
Crossover Comparison

We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy. Response was determined by using objective and subjective criteria. Thirty patients were randomly assigned to receive MCP alone at a dose of 2 mg/kg IV for three doses or the same dose of MCP plus 20 mg of DXM IV for three doses. Twenty evaluable patients received a second course of cisplatin and were crossed over to the opposite arm. Study results did not show a statistically significant advantage of combination MCP plus DXM over MCP alone using strict objective criteria for antiemetic response. However, patients subjectively preferred MCP plus DXM over MCP alone by nearly a 6:1 ratio, regardless of the randomization sequence. Although the addition of DXM does not appear to objectively improve emetic protection with high-dose MCP, we recommend MCP plus DXM to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy when the use of steroids is not contraindicated, in view of patient preference for the combination.

Sign in / Sign up

Export Citation Format

Share Document